# **OIE Reference Laboratory Reports Activities**Activities in 2021

This report has been submitted: 2022-01-13 21:23:45

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Aujeszky s disease
Address of laboratory:	ANSES Ploufragan/Plouzané/Niort laboratory Swine Virology and Immunology unit 41 rue de Beaucemaine B.P. 53 22440 Ploufragan - FRANCE
Tel.:	+33 (0)2 96 01 62 90
Fax:	+33 (0)2 96 01 62 94
E-mail address:	marie-frederique.lepotier@anses.fr
Website:	https://www.anses.fr/en/content/pig-virology-and-immunology-vip-unit-ploufragan-plouzan%C3%A9-niort-laboratory
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Nicolas ETERRADOSSI
Name (including Title and Position) of OIE Reference Expert:	Dr. Marie-Frédérique Le Potier Head of the swine virology and immunology unit Responsible for Aujeszky's disease OIE & national reference laboratory
Which of the following defines your laboratory? Check all that apply:	Governmental

#### ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)  Total number of test performed		est performed last year
Indirect diagnostic tests	agnostic tests		Internationally
ELISA gB Yes		1	0
ELISA gE Yes		34	0
Direct diagnostic tests		Nationally	Internationally
real time PCR Yes		40	0
virus isolation Yes		24	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

Yes

NOTE: Currently, there are 22 laboratories that produce Standard Reference Reagents officially recognised by the OIE for 19 diseases/pathogens. Please click the following link to the list of OIE-approved International Standard Sera: <a href="http://www.oie.int/en/our-scientific-expertise/veterinary-products/reference-reagents/">http://www.oie.int/en/our-scientific-expertise/veterinary-products/reference-reagents/</a>. If the reagent is not listed on this page, it is NOT considered OIE-approved. The next two questions allow you to indicate non-OIE-approved diagnostic reagents.

OIE-approved SRR producing laboratory - Select your lab from list:

Disease	Test	Available from
Aujeszky's disease	Enzyme-linked immunosorbent assay; Virus neutralisation	Dr Marie-Frédérique Le Potier Anses Ploufragan, Laboratoire de Ploufragan/Plouzané Unité de Virologie Immunologie Porcines Zoopole les Crox 22440 Ploufragan, France Tel: +33 (0)2 96 01 62 90 marie-frederique.lepotier@anses.fr

Type of reagent available	Related diagnostic test	Produced/ Supply imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient OIE Member Countries
reference serum ADV1	ELISA gB & gE	Produced	<pre></pre>	<pre>   &lt;10mL     10-100mL     100-500mL     &gt;500mL </pre>	LATVIA
reference serum ADV1	ELISA gB & gE	Produced	<pre></pre>	<pre></pre>	THE NETHERLANDS
International reference serum ADV1-gI-Q	ELISA gB & gE	Produced	<pre></pre>	<pre></pre>	LATVIA

<sup>3.</sup> Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
serum sub- standard ADV1 gB	ELISA gB	produced	24	7	3	□Africa □Americas □Asia and Pacific □Europe □Middle East
Sub-standard ADV1_gE	ELISA gE	produced	13	27	5	□Africa □Americas □Asia and Pacific ⊠Europe □Middle East
Positive control sera	ELISA gB & gE	produced	2	53	4	□Africa □Americas □Asia and Pacific ⊠Europe □Middle East
Negative control sera	ELISA gB & gE	produced	2	21	3	□Africa □Americas □Asia and Pacific □Europe □Middle East
AD virus inactivated strains strain	PCR	produced	3	0	1	□Africa □Americas □Asia and Pacific □Europe □Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

#### ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

#### ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
SINGAPORE	Virus neutralisation test	email
CHINA (PEOPLE'S REP. OF)	PCR ILCT	email
HUNGARY	ELISA reagents	email

### ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

#### ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory colle	ct epizootiological	data relevant to	international	disease control?

No

If the answer is no, please provide a brief explanation of the situation:

there is no list of national reference laboratory for AD available to be able to contact them and collect some data

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

The data are collected at national level by active and passive surveillance in domestic pigs, wild boars and other susceptible animals (dogs, cats, cattle)

#### 13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

- a) Articles published in peer-reviewed journals: 0
- b) International conferences: 0
- c) National conferences: 0
- d) Other:

(Provide website address or link to appropriate information) 1 Working group on Aujeszky's disease at national surveillance Platform https://www.plateforme-esa.fr/

#### ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

### ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025	Attestation accreditation-VIP.pdf
ISO 17043	

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
ELISA gB	COFRAC
ELISA gE	COFRAC
PCR	COFRAC
Virus isolation	COFRAC

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

No

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

#### ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

## ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

## ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <a href="http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing">http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing</a> see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
ILCT for ELISA gB and ELISA gE	27	□Africa ⊠Americas □Asia and Pacific ⊠Europe □Middle East

#### ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

probably due to the Covid19 situation , there was less technical consultancies than usually